{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:57:22Z","timestamp":1781719042396,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Wu Jieping Medical Foundation Clinical Research Special Fund","award":["320.6750.2024-18-89"],"award-info":[{"award-number":["320.6750.2024-18-89"]}]},{"name":"Wu Jieping Medical Foundation Clinical Research Special Fund","award":["320.6750.2024-6-107"],"award-info":[{"award-number":["320.6750.2024-6-107"]}]},{"name":"General Project of Postdoctoral Fund in Heilongjiang Province","award":["LBH-Z23216"],"award-info":[{"award-number":["LBH-Z23216"]}]},{"DOI":"10.13039\/501100011445","name":"Key Laboratory of Microbial Resources and Drug Development in Guizhou Province","doi-asserted-by":"publisher","award":["SKLSIM-2024141"],"award-info":[{"award-number":["SKLSIM-2024141"]}],"id":[{"id":"10.13039\/501100011445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Key Laboratory of Neurology and Oncology Drug Development Fund","award":["SKLSIM-2024142"],"award-info":[{"award-number":["SKLSIM-2024142"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13318-026-01001-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:50:22Z","timestamp":1777366222000},"page":"381-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalizing Liposomal Paclitaxel in Platinum-Based Combination Therapy for Gynecologic Cancers: Defining a Therapeutic Window Based on Tc>0.05 and CYP2C8 Metabolic Capacity"],"prefix":"10.1007","volume":"51","author":[{"given":"Shuai","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"1","key":"1001_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"1001_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2025.114066","volume":"311","author":"S Qiu","year":"2025","unstructured":"Qiu S, Jiang S, Ye Q, Yang Y, Li X. Global trends and geographical disparities in the incidence of uterine cancer from 1990 to 2021. Eur J Obstet Gynecol Reprod Biol. 2025;311:114066.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"1001_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et\u00a0al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1001_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s41043-025-00915-1","volume":"44","author":"T Feng","year":"2025","unstructured":"Feng T, Li W, Wang Q, Yang J, Shen F. Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. J Health Popul Nutr. 2025;44(1):208.","journal-title":"J Health Popul Nutr"},{"issue":"1","key":"1001_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li T, Zhang H, Lian M, He Q, Lv M, Zhai L, et\u00a0al. Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol. 2025;18(1):5.","journal-title":"J Hematol Oncol"},{"key":"1001_CR6","unstructured":"NCCN clinical practice guidelines in ovarian cancer fallopian tube cancer primary peritoneal cancer (2024 version 2). http:\/\/www.nccn.org"},{"issue":"9","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1073\/pnas.78.9.5608","volume":"78","author":"M De Brabander","year":"1981","unstructured":"De Brabander M, Geuens G, Nuydens R, et\u00a0al. Taxol induces the assemblyof free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A. 1981;78(9):5608\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2020.01.004","volume":"141","author":"X Cao","year":"2020","unstructured":"Cao X, Ganti AK, Stinchcombe T, Wong ML, Ho JC, Shen C, et\u00a0al. Predicting risk of chemotherapy-induced severe neutropenia: a pooled analysis in individual patients data with advanced lung cancer. Lung Cancer. 2020;141:14\u201320.","journal-title":"Lung Cancer"},{"issue":"Suppl 2","key":"1001_CR9","first-page":"S40","volume":"24","author":"S Tamburin","year":"2019","unstructured":"Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A, Argyriou AA. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S40\u201351.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2021.1856367","volume":"17","author":"DL Hertz","year":"2021","unstructured":"Hertz DL. Exploring pharmacogenetics of paclitaxel-and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. Expert Opin Drug Metab Toxicol. 2021;17(2):227\u201339.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1124\/jpet.117.240309","volume":"362","author":"A Henrich","year":"2017","unstructured":"Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, et\u00a0al. Semimechanistic bone marrow exhaustion pharmacokinetic\/pharmacodynamic model for chemotherapy-induced cumulative neutropenia. J Pharmacol Exp Ther. 2017;362(2):347\u201358.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3760\/cma.j.cn112152-20210422-00337","volume":"43","author":"XH Ma","year":"2021","unstructured":"Ma XH, Guo K, Dong WL, Jiang J. [Efficacy and safety of paclitaxel liposomes compared to paclitaxel combined with platinum in concurrent chemoradiotherapy for unresectable cervical carcinoma: a meta-analysis]. Zhonghua Zhong Liu Za Zhi. 2021;43(10):1132\u20139. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210422-00337. (Oct 23;).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"18","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-08-1046","volume":"14","author":"GJ Fetterly","year":"2008","unstructured":"Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, et\u00a0al. Pharmacokinetic\/pharmacodynamic modeling and simulation of neutropenia during Phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008;14(18):5856\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1046.","journal-title":"Clin Cancer Res"},{"key":"1001_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01731","volume":"10","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yan J, Chen W, Yang J, Liu M, Zhang Y, et\u00a0al. Population pharmacokinetics and exposure-safety relationship of paclitaxel liposome in patients with non-small cell lung cancer. Front Oncol. 2021;10:1731. https:\/\/doi.org\/10.3389\/fonc.2020.01731.","journal-title":"Front Oncol"},{"issue":"10","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s11095-012-0775-8","volume":"29","author":"S Ait-Oudhia","year":"2012","unstructured":"Ait-Oudhia S, Straubinger RM, Mager DE. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res. 2012;29(10):2833\u201344. https:\/\/doi.org\/10.1007\/s11095-012-0775-8. (Epub 2012 May 17.).","journal-title":"Pharm Res"},{"issue":"5","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2217\/pgs.13.33","volume":"14","author":"SD Krens","year":"2013","unstructured":"Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics. 2013;14(5):555\u201374.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.14678","volume":"87","author":"M Muth","year":"2021","unstructured":"Muth M, Ojara FW, Kloft C, Joerger M. Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol. 2021;87(2):306\u201316.","journal-title":"Br J Clin Pharmacol"},{"issue":"33","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.2174\/0929867324666170623093445","volume":"24","author":"NB Andriguetti","year":"2017","unstructured":"Andriguetti NB, Raymundo S, Antunes MV, Perassolo MS, Verza SG, Suyenaga ES, et\u00a0al. Pharmacogenetic and pharmacokinetic dose individualization of the taxane chemotherapeutic drugs paclitaxel and docetaxel. Curr Med Chem. 2017;24(33):3559\u201382.","journal-title":"Curr Med Chem"},{"key":"1001_CR19","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","volume":"11","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, et\u00a0al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11:4843\u201350.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-18-0656","volume":"24","author":"DL Hertz","year":"2018","unstructured":"Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, et\u00a0al. Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res. 2018;24(15):3602\u201310.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-017-3506-3","volume":"81","author":"M Ishikawa","year":"2018","unstructured":"Ishikawa M, Kawai M, Maeda T, Kagawa Y. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic. Cancer Chemother Pharmacol. 2018;81(2):399\u2013411.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1001_CR22","first-page":"444","volume":"29","author":"K Mross","year":"2006","unstructured":"Mross K, Hollander N, Frost A, Unger C, Ziroli V, Massing U. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. Onkologie. 2006;29(10):444\u201350.","journal-title":"Onkologie"},{"issue":"5","key":"1001_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00280-015-2724-9","volume":"75","author":"S Kraff","year":"2015","unstructured":"Kraff S, Nieuweboer AJ, Mathijssen RH, et\u00a0al. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol. 2015;75(5):975\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/FTD.0000000000000446","volume":"39","author":"M Joerger","year":"2017","unstructured":"Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, et\u00a0al. Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM). Ther Drug Monit. 2017;39(6):617\u201324.","journal-title":"Ther Drug Monit"},{"issue":"24","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1158\/1078-0432.CCR-04-1078","volume":"10","author":"AA Miller","year":"2004","unstructured":"Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004;10(24):8325\u201331.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1001_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/1574892813666180305170439","volume":"13","author":"DS Xin","year":"2018","unstructured":"Xin DS, Zhou L, Li CZ, Zhang SQ, Huang HQ, Qiu GD, et\u00a0al. TC>0.05 as a pharmacokinetic parameter of paclitaxel for therapeutic efficacy and toxicity in cancer patients. Recent Pat Anticancer Drug Discov. 2018;13(3):341\u20137.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"1001_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/2395-3977.192930","volume":"2","author":"SY Zhang","year":"2016","unstructured":"Zhang SY, Sun MY, Yuan Y, Wang MJ, She YQ, Zhou L, et\u00a0al. Correlation between paclitaxel TC>0.05 and its therapeutic efficacy and severe toxicities in ovarian cancer patients. Cancer Transl Med. 2016;2(5):131\u20136.","journal-title":"Cancer Transl Med"},{"issue":"14","key":"1001_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/fon-2018-0439","volume":"15","author":"G Han","year":"2019","unstructured":"Han G, Shi J, Mi L, Li N, Shi H, Li C, et\u00a0al. Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer. Future Oncol. 2019;15(14):1617\u201327.","journal-title":"Future Oncol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01001-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:25:25Z","timestamp":1781717125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01001-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients provided voluntary informed consent, and the study was approved by an institutional ethics committee (2020-32-IIT).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written\/verbal informed consent was obtained from all participants prior to participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants provided consent for data to be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}